Aydemir et al. examined the relationship between disease activity in rheumatoid arthritis (RA) and pain regulatory mechanisms of the central nervous system. They found that improvements in pain sensitivity were associated with reductions in disease activity in patients with RA after 12 weeks of treatment with disease-modifying anti-rheumatic drugs. This study underscores the importance of inflammatory and noninflammatory contributors to patient outcomes.
Latest News
Neutrophilic Inflammation in Spondyloarthritis
CHICAGO—In the basic science session, Beyond NETs: Alternative Roles of Neutrophils in Spondyloarthritis, neutrophils are explored as a common pathophysiologic thread among the spondyloarthropathies. In…
60-Day Comment Period Opens for FDA’s Draft Guidance on Biosimilars
The FDA has issued draft guidance recommending that all biosimilar medications be designated as interchangeable with their reference products upon initial FDA approval. A 60-day review and comment period of the draft guidance is now open, and the ACR will soon be submitting comments.
Extra Services Can Boost a Rheumatology Practice’s Profitability, Patient Care
Rheumatology practices can combat declining reimbursements with ancillary services. Experts discuss adding infusion, ultrasound & research services to boost revenue & patient care.
Tips for Recruiting & Onboarding Advanced Practice Providers
Experts share strategies for recruiting, onboarding & retaining APPs to address the rheumatologist shortage & improve patient access.
Independent Rheumatology Practices Face Challenges Amid Changing Landscape
At this Practice Innovation Summit session, experts discussed the challenges that come with surviving as an independent rheumatology practice in the current health environment.
